Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...

Artificial intelligence pushes us to rediscover thought and emotion, proving our value lies in meaning, not computation.

Our expectations about potential changes in a scene influence how we move our eyes, even when viewing static images.

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Most dogs aren't bred to feel at ease in our homes, but scientists studying puppy cognition have found ways you can help ...

Overthinking could be related to the constant back-and-forth between the brain's fear-processing centre or amygdala and the region governing social behaviour, according to a new study.

Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies.

Repetitive transcranial magnetic stimulation was superior to sham treatment for improving auditory verbal hallucinations in ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study Simufilam contin ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...

There are over 55 million people worldwide living with dementia in 2020. This number is expected to almost double every 20 ...

In this new analysis, the Company reported changes in plasma biomarkers that may reflect Alzheimer's disease pathology. The results demonstrated that individuals who entered the study with plasma ...